Valneva SE

Valneva SE, a French biotech leader, pioneers vaccine development with proprietary EB66 cells and IC31 adjuvant, tackling diseases from Japanese encephalitis to Zika.

Valneva’s VLA15 shows 93% Lyme vaccine efficacy, promising the first adult Lyme shot and a new growth pivot toward emerging markets.

Valneva SE to report 2025 results on March 18 2026 amid VLA15 Phase‑3 data release, aiming for first commercial Lyme vaccine launch before 2028.

Valneva’s stock falls after US chikungunya vaccine withdrawal; company pivots to Lyme vaccine with Pfizer to restore investor confidence.

Valneva drops its U.S. Chikungunya vaccine plans, shares tumble, and it pivots to a promising Lyme‑disease partnership with Pfizer—what this means for investors.

Valneva SE, a French biotechnology company, navigated a challenging year with opportunities for growth, despite financial losses and regulatory hurdles, as it continues to develop vaccines for infectious diseases.

The European Medicines Agency (EMA) has lifted its temporary restriction on Valneva’s chikungunya vaccine, IXCHIQ, for individuals aged 65 and above, allowing its use in vulnerable populations.